Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE ...

Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients ...

The marketing and selling of SANTYL Ointment builds upon HEALTHPOINT's announcement in March 2006 that it purchased the topical collagenase business from BioSpecifics Technologies Corp. As a ...

Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes Study to support EscharEx® BLA submission and strengthen commercialization ...

Complete debridement at 2 weeks was achieved in 63% of EscharEx-treated patients, compared to 0% in the SANTYL group (p = 0.001). Median time to debridement was 9 days for EscharEx vs. not ...